52 related articles for article (PubMed ID: 32781097)
1. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
Kaderi MA; Kanduri M; Buhl AM; Sevov M; Cahill N; Gunnarsson R; Jansson M; Smedby KE; Hjalgrim H; Jurlander J; Juliusson G; Mansouri L; Rosenquist R
Haematologica; 2011 Aug; 96(8):1153-60. PubMed ID: 21508119
[TBL] [Abstract][Full Text] [Related]
2. Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23.
Kaaks R; Sookthai D; Łuczyńska A; Oakes CC; Becker S; Johnson T; Johansson A; Melin B; Sjöberg K; Trichopoulos D; Trichopoulou A; Lagiou P; Mattiello A; Tumino R; Masala G; Agnoli C; Boeing H; Aleksandrova K; Brennan P; Franceschi S; Roulland S; Casabonne D; de Sanjose S; Sánchez MJ; Huerta JM; Ardanaz E; Sala N; Overvad K; Tjønneland A; Halkjær J; Weiderpass E; Bueno-de-Mesquita HB; Vermeulen R; Peeters PH; Vineis P; Kelly RS; Khaw KT; Travis RC; Key TJ; Riboli E; Nieters A
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):538-45. PubMed ID: 25542829
[TBL] [Abstract][Full Text] [Related]
3. Prognostication of chronic lymphocytic leukemia in the era of new agents.
Eichhorst B; Hallek M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.
Zent CS; Kay NE
Leuk Lymphoma; 2011 Aug; 52(8):1425-34. PubMed ID: 21649549
[TBL] [Abstract][Full Text] [Related]
5. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Anthoine G; Mineur P; Bron D; Lagneaux L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862275
[TBL] [Abstract][Full Text] [Related]
6. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
Jilani I; Wei C; Bekele BN; Zhang ZJ; Keating M; Wierda W; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien SM; Giles FJ; Albitar M
Int J Lab Hematol; 2009 Feb; 31(1):97-105. PubMed ID: 18190591
[TBL] [Abstract][Full Text] [Related]
7. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.
Syrykh C; Pons-Brun B; Russiñol N; Playa-Albinyana H; Baumann T; Duran-Ferrer M; Kulis M; Carbó-Meix A; Mozas P; Alcoceba M; González M; Navarro-Bailón A; Colado E; Payer ÁR; Aymerich M; Terol MJ; Lu J; Knisbacher BA; Hahn CK; Ruiz-Gaspà S; Enjuanes A; Wu CJ; Getz G; Zenz T; López-Guillermo A; Martín-Subero JI; Colomer D; Delgado J; Campo E; Nadeu F
Blood Adv; 2023 Dec; 7(23):7384-7391. PubMed ID: 37505099
[No Abstract] [Full Text] [Related]
8. Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia.
Fegan G; Tod D; Downing A; Elmusharaf N; Pepper C; Fegan C
Haematologica; 2024 May; 109(5):1566-1569. PubMed ID: 38268485
[No Abstract] [Full Text] [Related]
9. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.
Eltahir M; Fletcher E; Dynesius L; Jarblad JL; Lord M; Laurén I; Zekarias M; Yu X; Cragg MS; Hammarström C; Levedahl KH; Höglund M; Ullenhag G; Mattsson M; Mangsbo SM
Int Immunopharmacol; 2021 Jan; 90():107226. PubMed ID: 33316742
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of targeted therapies for diffuse large B cell lymphoma.
Wang J; Huang J; Zeng Q
BMC Cancer; 2020 Dec; 20(1):1218. PubMed ID: 33308179
[TBL] [Abstract][Full Text] [Related]
11. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA; Taverna C; Schär S; Vanazzi A; Rondeau S; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Raats J; Rauch D; Vorobiof DA; Lohri A; Ruegsegger C; Biaggi Rudolf C; Rusterholz C; Hayoz S; Ghielmini M; Zucca E
Blood Adv; 2020 Dec; 4(23):5951-5957. PubMed ID: 33275769
[TBL] [Abstract][Full Text] [Related]
12. Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab.
Wakiya R; Kameda T; Takeuchi Y; Ozaki H; Nakashima S; Shimada H; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jan; 5(1):145-151. PubMed ID: 33269653
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED; Burggraaff CN; Nijland M; Bakunina K; Mous R; Lugtenburg PJ; Dierickx D; van Imhoff GW; Vermaat JSP; Marijt EAF; Visser O; Mandigers C; Bilgin YM; Beeker A; Durian MF; van Rees B; Bohmer LH; Tick LW; Boersma RS; Snijders TJF; Schouten HC; Koene HR; de Jongh E; Hijmering N; Diepstra A; van den Berg A; Arens AIJ; Huijbregts J; Hoekstra O; Zijlstra JM; de Jong D; Kersten MJ
Haematologica; 2020 Dec; 105(12):2805-2812. PubMed ID: 33256379
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09).
Kang S; Cho H; Sohn BS; Oh SY; Lee WS; Lee SM; Yang DH; Huh J; Yoon DH; Suh C
Ann Hematol; 2020 Dec; 99(12):2831-2836. PubMed ID: 32989495
[TBL] [Abstract][Full Text] [Related]
15. SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders.
Kľoc D; Kurhajec S; Huniadi M; Sýkora J; Guman T; Šarišský M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612827
[TBL] [Abstract][Full Text] [Related]
16. Quantitative proteomics characterization of cancer biomarkers and treatment.
Yang XL; Shi Y; Zhang DD; Xin R; Deng J; Wu TM; Wang HM; Wang PY; Liu JB; Li W; Ma YS; Fu D
Mol Ther Oncolytics; 2021 Jun; 21():255-263. PubMed ID: 34095463
[TBL] [Abstract][Full Text] [Related]
17. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saberi Hosnijeh F; van der Straten L; Kater AP; van Oers MHJ; Posthuma WFM; Chamuleau MED; Bellido M; Doorduijn JK; van Gelder M; Hoogendoorn M; de Boer F; Te Raa GD; Kerst JM; Marijt EWA; Raymakers RAP; Koene HR; Schaafsma MR; Dobber JA; Tonino SH; Kersting SS; Langerak AW; Levin MD
Exp Hematol; 2020 Sep; 89():55-60.e6. PubMed ID: 32781097
[TBL] [Abstract][Full Text] [Related]
18. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
